Active ingredientVosoritideCat. No. P-V065-001CAS 1480724-61-5Family · Pharmaceutical analytical standards
Vosoritide
An analogue of C-type natriuretic peptide, approved in 2021 in Europe and the United States to promote growth in height in children with achondroplasia. This family brings together the active ingredient and other impurities.
Did you know?It was the first medicine approved to improve growth in achondroplasia, the most common form of dwarfism: it counteracts the overactivity of the FGFR3 gene, which holds back bone growth.
Go to the active ingredient →Active ingredientVosoritideCat. No. P-V065-001CAS 1480724-61-5
ImpurityVosoritide D-Asp-29 ImpurityCat. No. P-V065-002
ImpurityVosoritide D-Cys-23 ImpurityCat. No. P-V065-003
ImpurityVosoritide D-Cys-39 ImpurityCat. No. P-V065-004
ImpurityVosoritide D-His-5 ImpurityCat. No. P-V065-005
ImpurityVosoritide D-Ser-20 ImpurityCat. No. P-V065-007
ImpurityVosoritide D-Ser-33 ImpurityCat. No. P-V065-008
ImpurityVosoritide Des Glu-4 ImpurityCat. No. P-V065-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.